Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Sci Rep ; 11(1): 6653, 2021 03 23.
Artículo en Inglés | MEDLINE | ID: mdl-33758236

RESUMEN

The present study examines the association between the ceremonial use of ayahuasca-a decoction combining the Banistereopsis caapi vine and N,N-Dimethyltryptamine-containing plants-and changes in personality traits as conceived by the Five-Factor model (FFM). We also examine the degree to which demographic characteristics, baseline personality, and acute post-ayahuasca experiences affect personality change. Participants recruited from three ayahuasca healing and spiritual centers in South and Central America (N = 256) completed self-report measures of personality at three timepoints (Baseline, Post, 3-month Follow-up). Informant-report measures of the FFM were also obtained (N = 110). Linear mixed models were used to examine changes in personality and the moderation of those changes by covariates. The most pronounced change was a reduction in Neuroticism dzself-reportT1-T2 = - 1.00; dzself-reportT1-T3 = - .85; dzinformant-reportT1-T3 = - .62), reflected in self- and informant-report data. Moderation of personality change by baseline personality, acute experiences, and purgative experiences was also observed.


Asunto(s)
Banisteriopsis/química , Conducta Ceremonial , Personalidad/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Chamanismo , Alucinógenos/administración & dosificación , Alucinógenos/química , Humanos , N,N-Dimetiltriptamina/administración & dosificación , N,N-Dimetiltriptamina/química , Trastornos de la Personalidad/diagnóstico , Trastornos de la Personalidad/etiología , Extractos Vegetales/química , Factores de Riesgo , Autoinforme
2.
Psychopharmacology (Berl) ; 237(10): 3161-3171, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32700023

RESUMEN

Ayahuasca is a psychoactive plant brew containing dimethyltryptamine (DMT) and monoamine oxidase inhibitors (MAOIs). It originates from the Amazon basin, where it is used primarily for ceremonial purposes. Ayahuasca tourists are now entering certain communities seeking alternative physical or psychological healing, as well as spiritual growth. RATIONALE: Recent evidence has shown that the similar acting psychedelic compound, psilocybin, facilitated long-term increases in trait openness following a single administration. OBJECTIVES: This paper assesses the impact of ayahuasca on personality in a traditional framework catering for ayahuasca tourists. METHOD: Within a mixed design, we examined the effect of ayahuasca on participants' personality (measured by the NEO Personality Inventory 3 questionnaire) across time (pre- to post-ayahuasca administration, and 6-month follow-up), relative to a comparison group (who did not ingest ayahuasca). RESULTS: The results demonstrated significant increases in agreeableness pre- and post-ayahuasca administration and significant reductions in neuroticism in 24 participants, relative to the comparison group. Both of these changes were sustained at 6-month follow-up, and trait level increases were also observed in openness at this stage. Additionally, greater perceived mystical experience (measured using the Mystical Experience Questionnaire 30) was associated with increased reductions in neuroticism. CONCLUSIONS: These findings, which indicate a positive mediating effect of ayahuasca on personality, support the growing literature suggesting potential therapeutic avenues for serotonergic psychedelics.


Asunto(s)
Banisteriopsis , Alucinógenos/farmacología , Turismo Médico/psicología , Neuroticismo/efectos de los fármacos , Personalidad/efectos de los fármacos , Extractos Vegetales/farmacología , Adulto , Banisteriopsis/química , Femenino , Estudios de Seguimiento , Alucinógenos/aislamiento & purificación , Humanos , Masculino , Turismo Médico/tendencias , Inhibidores de la Monoaminooxidasa/aislamiento & purificación , Inhibidores de la Monoaminooxidasa/farmacología , Misticismo/psicología , N,N-Dimetiltriptamina/aislamiento & purificación , N,N-Dimetiltriptamina/farmacología , Neuroticismo/fisiología , Personalidad/fisiología , Perú/epidemiología , Extractos Vegetales/aislamiento & purificación , Psilocibina/aislamiento & purificación , Psilocibina/farmacología , Encuestas y Cuestionarios
3.
J Psychoactive Drugs ; 52(3): 264-272, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32362241

RESUMEN

Ayahuasca is a psychoactive brew that contains N,N-dimethyltryptamine and monoamine oxidase-inhibiting alkaloids. It is originally from the Amazon rainforest, but since the 1990s it has expanded worldwide. The compound is used in different religious, spiritual, and therapeutic settings. One of its common applications is for the treatment of addiction. The current study is an assessment of the impact of ayahuasca on personality traits in former substance users from Catalonia and surrounding areas. When compared with a control group, the ayahuasca group had statistically significantly higher scores in the dimensions Novelty Seeking and Self-Transcendence, and in the traits Attachment, Impulsivity, Compassion, and Spiritual Acceptance. Results suggest that recovery could be related less to a reduction of Impulsivity and Novelty Seeking, main features of substance use disorder (SUD), and more to an increase of Character dimensions and traits, especially Self-Transcendence and Cooperativeness. Those changes could be triggered by self-reflective, prosocial, and transcendental ayahuasca ritual experiences, which in the qualitative part of the research were described by the participants as being of great importance for their recovery, helping with the reconstruction of personal goals, gratifications, social bonds, and the general life's projection.


Asunto(s)
Banisteriopsis , Consumidores de Drogas/psicología , Personalidad/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Trastornos Relacionados con Sustancias/tratamiento farmacológico , Adulto , Estudios de Casos y Controles , Conducta Ceremonial , Femenino , Humanos , Masculino , Persona de Mediana Edad , España
4.
Sci Rep ; 10(1): 4075, 2020 03 05.
Artículo en Inglés | MEDLINE | ID: mdl-32139811

RESUMEN

Ayahuasca is a hallucinogenic decoction used as a traditional medicine in several Amazonian regions. The ritualistic use of ayahuasca has spread throughout many countries, making it necessary to study its risks and benefits. Two sub-studies were designed for this investigation. In sub-study 1, a psychiatric interview and a battery of questionnaires were administered to subjects (n = 40) before their first ayahuasca use. Two follow-ups were conducted at 1 and 6 months. In sub-study 2, the same interview and battery of questionnaires were administered to long-term ayahuasca users (n = 23) and their scores were compared with those of the ayahuasca-naïve group. In the first assessment, nearly half (45%) of the naïve users were found to meet the diagnostic criteria for a psychiatric disorder. After the ayahuasca use, more than 80% of those subjects showed clinical improvements that persisted at 6 months. The questionnaires showed significant reductions in depression and psychopathology. Regarding sub-study 2, long-term users showed lower depression scores, and higher scores for self-transcendence and quality of life, as compared to their peers in sub-study 1. Further controlled and observational naturalistic studies assessing the eventual risks and potential benefits of ayahuasca are warranted.


Asunto(s)
Banisteriopsis/química , Alucinógenos/efectos adversos , Trastornos Mentales/inducido químicamente , Salud Mental , Personalidad/efectos de los fármacos , Calidad de Vida , Adulto , Anciano , Estudios Transversales , Femenino , Humanos , Entrevista Psicológica , Estudios Longitudinales , Masculino , Trastornos Mentales/patología , Persona de Mediana Edad , Psicopatología , Encuestas y Cuestionarios , Adulto Joven
5.
Eur Neuropsychopharmacol ; 33: 71-80, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32146028

RESUMEN

A single dose of the serotonin 2A receptor (5-HT2AR) agonist psilocybin can have long-lasting beneficial effects on mood, personality, and potentially on mindfulness, but underlying mechanisms are unknown. Here, we for the first time conduct a study that assesses psilocybin effects on cerebral 5-HT2AR binding with [11C]Cimbi-36 positron emission tomography (PET) imaging and on personality and mindfulness. Ten healthy and psychedelic-naïve volunteers underwent PET neuroimaging of 5-HT2AR at baseline (BL) and one week (1W) after a single oral dose of psilocybin (0.2-0.3 mg/kg). Personality (NEO PI-R) and mindfulness (MAAS) questionnaires were completed at BL and at three-months follow-up (3M). Paired t-tests revealed statistically significant increases in personality Openness (puncorrected = 0.04, mean change [95%CI]: 4.2[0.4;∞]), which was hypothesized a priori to increase, and mindfulness (pFWER = 0.02, mean change [95%CI]: 0.5 [0.2;0.7]). Although 5-HT2AR binding at 1W versus BL was similar across individuals (puncorrected = 0.8, mean change [95%CI]: 0.007 [-0.04;0.06]), a post hoc linear regression analysis showed that change in mindfulness and 5-HT2AR correlated negatively (ß [95%CI] = -5.0 [-9.0; -0.9], pFWER= 0.046). In conclusion, we confirm that psilocybin intake is associated with long-term increases in Openness and - as a novel finding - mindfulness, which may be a key element of psilocybin therapy. Cerebral 5-HT2AR binding did not change across individuals but the negative association between changes in 5-HT2AR binding and mindfulness suggests that individual change in 5-HT2AR levels after psilocybin is variable and represents a potential mechanism influencing long-term effects of psilocybin on mindfulness.


Asunto(s)
Alucinógenos/administración & dosificación , Alucinógenos/farmacología , Atención Plena , Neocórtex/efectos de los fármacos , Neocórtex/metabolismo , Psilocibina/administración & dosificación , Psilocibina/farmacología , Receptor de Serotonina 5-HT2A/efectos de los fármacos , Receptor de Serotonina 5-HT2A/metabolismo , Adulto , Bencilaminas , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Neocórtex/diagnóstico por imagen , Pruebas Neuropsicológicas , Personalidad/efectos de los fármacos , Pruebas de Personalidad , Fenetilaminas , Tomografía de Emisión de Positrones , Adulto Joven
6.
Med Hypotheses ; 134: 109406, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31634774

RESUMEN

We introduce a novel hypothesis which states that the therapeutic utilisation of psilocybin has beneficial effects on genetic aging. Ex hypothesi, we predict a priori that controlled psilocybin interventions exert quantifiable positive impact on leucocyte telomere length (telomeres are a robust predictor of mortality and multifarious aging-related diseases). Our hypothesising follows the Popperian logic of scientific discovery, viz., bold (and refutable) conjectures form the very foundation of scientific progress. The 'psilocybin-telomere hypothesis' is formalised as a logically valid deductive (syllogistic) argument and we provide substantial evidence to support the underlying premises. Impetus for our theorising derives from a plurality of converging empirical sources indicating that psilocybin has persistent beneficial effects on various aspects of mental health (e.g., in the context of depression, anxiety, PTSD, OCD, addiction, etc.). Additional support is based on a large corpus of studies that establish reliable correlations between mental health and telomere attrition (improved mental health is generally correlated with longer telomeres). Another pertinent component of our argument is based on recent studies which demonstrate that "meditative states of consciousness" provide beneficial effects on genetic aging. Similarly, psilocybin can induce states of consciousness that are neurophysiologically and phenomenologically significantly congruent with meditative states. Furthermore, prior research has demonstrated that a single dose of psilocybin can occasion life-changing transformative experiences (≈ 70% of healthy volunteers rate their experience with psilocybin amongst the five personally most meaningful lifetime events, viz., ranked next to giving birth to a child or losing a loved one). We postulate that these profound psychological events leave quantifiable marks at the molecular genetic/epigenetic level. Given the ubiquitous availability and cost effectiveness of telomere length assays, we suggest that quantitative telomere analysis should be regularly included in future psilocybin studies as an adjunctive biological marker (i.e., to facilitate scientific consilience via methodological triangulation). In order to substantiate the 'psilocybin-telomere hypothesis' potential neuropsychopharmacological, endocrinological, and genetic mechanisms of action are discussed (e.g., HPA-axis reactivity, hippocampal neurogenesis, neurotropic growth factors such as BDNF, 5-HT2A receptor agonism, neuroplasticity/synaptoplasticity, brain-wide alterations in neuronal functional connectivity density, involvement of the SLC6A4 serotonin transporter gene, inter alia). The proposed research agenda is thus intrinsically highly interdisciplinary, and it has deep ramifications from a philosophy of science perspective as it connects the epistemic level (qualitative experiential phenomenology) with the ontic level (quantitative molecular genetics) of analysis. In the long term, multidisciplinary and innovative investigations of the 'psilocybin-telomere hypothesis' could contribute to the improvement of senotherapeutic psychological interventions and the identification of novel geroprotective and neuroprotective/restorative pharmaceutical targets to decelerate genetic aging and improve well-being and quality of life during the aging process.


Asunto(s)
Envejecimiento/efectos de los fármacos , Modelos Genéticos , Modelos Psicológicos , Psilocibina/uso terapéutico , Psicotrópicos/uso terapéutico , Acortamiento del Telómero/efectos de los fármacos , Envejecimiento/genética , Envejecimiento/psicología , Envejecimiento Prematuro/tratamiento farmacológico , Envejecimiento Prematuro/genética , Envejecimiento Prematuro/prevención & control , Animales , Ansiedad/tratamiento farmacológico , Ansiedad/genética , Factor Neurotrófico Derivado del Encéfalo/fisiología , Estado de Conciencia/efectos de los fármacos , Metilación de ADN/efectos de los fármacos , Depresión/tratamiento farmacológico , Depresión/genética , Modelos Animales de Enfermedad , Sistema Endocrino/fisiopatología , Humanos , Neurotransmisores/fisiología , Estrés Oxidativo/efectos de los fármacos , Personalidad/efectos de los fármacos , Psilocibina/farmacología , Psicotrópicos/farmacología , Proyectos de Investigación , Proteínas de Transporte de Serotonina en la Membrana Plasmática/fisiología , Estrés Psicológico/tratamiento farmacológico , Estrés Psicológico/genética , Acortamiento del Telómero/fisiología
7.
Psychopharmacology (Berl) ; 235(10): 2979-2989, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30105399

RESUMEN

RATIONALE: Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on mental health-related parameters and less on long-term effects. OBJECTIVES: The present study aimed to assess sub-acute and long-term effects of ayahuasca on well-being and cognitive thinking style. The second objective was to assess whether sub-acute and long-term effects of ayahuasca depend on the degree of ego dissolution that was experienced after consumption of ayahuasca. RESULTS: Ayahuasca ceremony attendants (N = 57) in the Netherlands and Colombia were assessed before, the day after, and 4 weeks following the ritual. Relative to baseline, ratings of depression and stress significantly decreased after the ayahuasca ceremony and these changes persisted for 4 weeks. Likewise, convergent thinking improved post-ayahuasca ceremony up until the 4 weeks follow-up. Satisfaction with life and several aspects of mindfulness increased the day after the ceremony, but these changes failed to reach significance 4 weeks after. Changes in affect, satisfaction with life, and mindfulness were significantly correlated to the level of ego dissolution experienced during the ayahuasca ceremony and were unrelated to previous experience with ayahuasca. CONCLUSION: It is concluded that ayahuasca produces sub-acute and long-term improvements in affect and cognitive thinking style in non-pathological users. These data highlight the therapeutic potential of ayahuasca in the treatment of mental health disorders, such as depression.


Asunto(s)
Banisteriopsis , Cognición/efectos de los fármacos , Alucinógenos/farmacología , Personalidad/efectos de los fármacos , Extractos Vegetales/farmacología , Psicotrópicos/farmacología , Pensamiento/efectos de los fármacos , Adulto , Afecto/efectos de los fármacos , Depresión/diagnóstico , Ego , Femenino , Humanos , Países Bajos , Satisfacción Personal , América del Sur , Estrés Psicológico/diagnóstico
8.
Int J Clin Exp Hypn ; 61(3): 282-304, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23679112

RESUMEN

This study proposes a strategy, based on self-regulation therapy, to change personality and its biological substrate, the DRD3 gene expression. It has been demonstrated that acute doses of stimulating drugs, like methylphenidate, are able to change personality and the expression of certain genes in the short term. On the other hand, self-regulation therapy has been proven to reproduce the effects of drugs. Thus, it is feasible to hope that self-regulation therapy is equally effective as methylphenidate in changing personality and the gene expression. This is a preliminary study with a single-case experimental design with replication in which 2 subjects participated. The results and potential implications for research and psychotherapy are discussed.


Asunto(s)
Personalidad , Receptores de Dopamina D3/biosíntesis , Sugestión , Estimulantes del Sistema Nervioso Central/farmacología , Femenino , Expresión Génica/efectos de los fármacos , Humanos , Masculino , Metilfenidato/farmacología , Persona de Mediana Edad , Personalidad/efectos de los fármacos , Inventario de Personalidad
9.
Drug Test Anal ; 4(7-8): 601-9, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22761152

RESUMEN

Ayahuasca is a psychedelic brew originally used for magico-religious purposes by Amerindian populations of the western Amazon Basin. Throughout the last four decades, the use of ayahuasca spread towards major cities in all regions of Brazil and abroad. This trend has raised concerns that regular use of this N,N-dimethyltryptamine- and harmala-alkaloid-containing tea may lead to mental and physical health problems associated typically with drug abuse. To further elucidate the mental and physical health of ayahuasca users, we conducted a literature search in the international medical PubMed database. Inclusion criteria were evaluation of any related effect of ayahuasca use that occurred after the resolution of acute effects of the brew. Fifteen publications were related to emotional, cognitive, and physical health of ayahuasca users. The accumulated data suggest that ayahuasca use is safe and may even be, under certain conditions, beneficial. However, methodological bias of the reviewed studies might have contributed to the preponderance of beneficial effects and to the few adverse effects reported. The data up to now do not appear to allow for definitive conclusions to be drawn on the effects of ayahuasca use on mental and physical health, but some studies point in the direction of beneficial effects. Additional studies are suggested to provide further clarification.


Asunto(s)
Banisteriopsis/química , Alucinógenos/farmacología , N,N-Dimetiltriptamina/farmacología , Extractos Vegetales/farmacología , Brasil , Cognición/efectos de los fármacos , Estado de Salud , Humanos , Personalidad/efectos de los fármacos , Religión
10.
Psychosomatics ; 51(4): 340-4, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20587764

RESUMEN

BACKGROUND: For decades, anabolic-androgenic steroids have been abused to enhance muscle growth. The harm inflicted by these compounds is well documented. OBJECTIVE: The authors investigated and report on a case in which a male patient self-prescribed some newer dietary supplements, about which less is known. METHOD: The authors report on a case of hepatitis and aggressive personality changes in a 31-year-old man taking purported prohormone agent SUS500 and other, newer supplements. RESULTS: Diagnosis was based on history, mental status exam, and laboratory findings. With discontinuation of all supplements and supportive care, the patient's personality changes resolved, and normal liver function returned. CONCLUSION: The authors conclude that newer anabolic supplements may cause some of the same side effects as traditional steroid hormones.


Asunto(s)
Anabolizantes/envenenamiento , Andrógenos/envenenamiento , Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico , Trastornos de la Personalidad/inducido químicamente , Personalidad/efectos de los fármacos , Acetilcisteína/administración & dosificación , Enfermedad Aguda , Adulto , Agresión/efectos de los fármacos , Enfermedad Hepática Inducida por Sustancias y Drogas/complicaciones , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Suplementos Dietéticos , Doping en los Deportes/métodos , Doping en los Deportes/psicología , Fatiga/complicaciones , Ácido Fólico/administración & dosificación , Estudios de Seguimiento , Humanos , Genio Irritable/efectos de los fármacos , Masculino , Debilidad Muscular/complicaciones , Trastornos de la Personalidad/terapia , Trastornos del Inicio y del Mantenimiento del Sueño/inducido químicamente , Trastornos del Inicio y del Mantenimiento del Sueño/complicaciones , Esteroides/efectos adversos , Tiamina/administración & dosificación , Levantamiento de Peso
11.
J Nerv Ment Dis ; 184(2): 86-94, 1996 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8596116

RESUMEN

A multinational, collaborative, biomedical investigation of the effects of hoasca (ayahuasca), a potent concoction of plant hallucinogens, was conducted in the Brazilian Amazon during the summer of 1993. This report describes the psychological assessment of 15 long-term members of a syncretic church that utilizes hoasca as a legal, psychoactive sacrament as well as 15 matched controls with no prior history of hoasca ingestion. Measures administered to both groups included structured psychiatric diagnostic interviews, personality testing, and neuropsychological evaluation. Phenomenological assessment of the altered state experience as well as semistructured and open-ended life story interviews were conducted with the long-term use hoasca group, but not the hoasca-naive control group. Salient findings included the remission of psychopathology following the initiation of hoasca use along with no evidence of personality or cognitive deterioration. Overall assessment revealed high functional status. Implications of this unusual phenomenon and need for further investigation are discussed.


Asunto(s)
Alucinógenos/farmacología , Plantas Medicinales , Religión y Medicina , Adulto , Brasil/epidemiología , Cognición/efectos de los fármacos , Harmina/farmacología , Humanos , Magia , Masculino , Medicina Tradicional , Trastornos Mentales/diagnóstico , Trastornos Mentales/epidemiología , Persona de Mediana Edad , Pruebas Neuropsicológicas , Personalidad/efectos de los fármacos , Escalas de Valoración Psiquiátrica , Trastornos Relacionados con Sustancias/diagnóstico , Trastornos Relacionados con Sustancias/psicología , , Aprendizaje Verbal/efectos de los fármacos
12.
Drug Alcohol Depend ; 25(3): 253-6, 1990 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-2347289

RESUMEN

The levels of trait anxiety and trait anger were compared for adult clients in residential treatment with primary diagnoses of alcoholism, cannabis dependence, cocaine abuse and opioid dependence. With a sample of 809 clients results suggested each of these groups to have significantly elevated anxiety and anger scores, compared to non-client samples. However, there were no significant differences on either anxiety or anger scores based on drug of choice.


Asunto(s)
Ira , Ansiedad/complicaciones , Cocaína , Etanol , Abuso de Marihuana/psicología , Trastornos Relacionados con Opioides/psicología , Opio , Trastornos Relacionados con Sustancias/psicología , Adulto , Femenino , Humanos , Masculino , Personalidad/efectos de los fármacos , Factores Sexuales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA